Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Go back to Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)| (NASDAQ: SRRK) | Delayed: 49.19 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.19 | 52 Week High | $ | |||
| Open | $49.19 | 52 Week Low | $ | |||
| Day High | $49.19 | P/E | N/A | |||
| Day Low | $49.19 | EPS | $ | |||
| Volume | 13,248 | |||||
